{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:09:11Z","timestamp":1791284951865,"version":"4.1.0"},"reference-count":45,"publisher":"The Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context:<\/jats:title>\n                    <jats:p>Myostatin is a negative regulator of muscle growth. Androgen deprivation (ADT) is associated with muscle loss and increased body fat, and currently available therapies have limited efficacy to treat this complication. The antimyostatin peptibody (AMG 745\/Mu-S) markedly attenuated muscle loss and decreased fat accumulation in orchiectomized mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective of the study was to evaluate the safety, pharmacokinetics, and muscle efficacy of AMG 745 in men undergoing ADT for nonmetastatic prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a randomized, blinded, placebo-controlled, multiple-dose, phase 1 study of AMG 745 given for 28 days. The end point of percentage change from baseline in lean body mass (LBM) as assessed by dual x-ray absorptiometry was prespecified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Rates of adverse events (AMG 745 vs placebo) were the following: diarrhea (13% vs 9%), fatigue (13% vs 4%), contusion (10% vs 0%), and injection site bruising (6% vs 4%). Exposure increased linearly from 0.3 mg\/kg to 3 mg\/kg. AMG 745 significantly increased LBM in the 3 mg\/kg vs the placebo groups on day 29 by 2.2% (\u00b10.8% SE, P = 0.008); in exploratory fat mass analysis, a decrease of \u22122.5% (\u00b11.0% SE, P = 0.021) was observed. Pharmacodynamic changes in muscle and fat were maintained at follow-up, 1 month after day 29.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Four weekly sc doses of AMG 745 were well tolerated and were associated with increased LBM and decreased fat in the men receiving ADT for nonmetastatic prostate cancer. Results support further investigation of AMG 745 in clinical settings with muscle loss and atrophy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jc.2014-1271","type":"journal-article","created":{"date-parts":[[2014,6,27]],"date-time":"2014-06-27T13:12:13Z","timestamp":1403874733000},"page":"E1967-E1975","source":"Crossref","is-referenced-by-count":77,"title":["Pharmacological Inhibition of Myostatin and Changes in Lean Body Mass and Lower Extremity Muscle Size in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer"],"prefix":"10.1210","volume":"99","author":[{"given":"Desmond","family":"Padhi","sequence":"first","affiliation":[{"name":"Department of Medical Sciences (D.P.), Thousand Oaks, California 91320"},{"name":"Amgen Inc (D.P.), Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestia S.","family":"Higano","sequence":"additional","affiliation":[{"name":"Department of Medicine (C.S.H.), University of Washington, and Fred Hutchinson Cancer Research Center, Seattle, Washington 98109"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[{"name":"Carolina Urologic Research Center, (N.D.S.), Myrtle Beach, South Carolina 29579"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sieber","sequence":"additional","affiliation":[{"name":"Urological Associates of Lancaster (P.S.), Lancaster, Pennsylvania 17604"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Biostatistics (E.R.), Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center (M.R.S.), Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"issue":"4","key":"2020071616441601300_B1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/SPC.0b013e32834bddf9","article-title":"Targeting the myostatin signaling pathway to treat muscle wasting diseases","volume":"5","author":"Han","year":"2011","journal-title":"Curr Opin Suppl Palliat Care"},{"issue":"3","key":"2020071616441601300_B2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00075197-200405000-00004","article-title":"Myostatin: a therapeutic target for skeletal muscle wasting","volume":"7","author":"Roth","year":"2004","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"51","key":"2020071616441601300_B3","doi-asserted-by":"crossref","first-page":"49831","DOI":"10.1074\/jbc.M204291200","article-title":"Myostatin inhibits myoblast differentiation by down-regulating MyoD expression","volume":"277","author":"Langley","year":"2002","journal-title":"J Biol Chem"},{"issue":"3","key":"2020071616441601300_B4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s003359900727","article-title":"Molecular definition of an allelic series of mutations disrupting the myostatin function and causing double-muscling in cattle","volume":"9","author":"Grobet","year":"1998","journal-title":"Mammal Genome"},{"issue":"8","key":"2020071616441601300_B5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s003359900843","article-title":"A deletion in the myostatin gene causes the compact (Cmpt) hypermuscular mutation in mice","volume":"9","author":"Szabo","year":"1998","journal-title":"Mammal Genome"},{"issue":"1","key":"2020071616441601300_B6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/ng0997-71","article-title":"A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle","volume":"17","author":"Grobet","year":"1997","journal-title":"Nat Genet"},{"issue":"9","key":"2020071616441601300_B7","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1101\/gr.7.9.910","article-title":"Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle","volume":"7","author":"Kambadur","year":"1997","journal-title":"Genome Res"},{"issue":"23","key":"2020071616441601300_B8","doi-asserted-by":"crossref","first-page":"12457","DOI":"10.1073\/pnas.94.23.12457","article-title":"Double muscling in cattle due to mutations in the myostatin gene","volume":"94","author":"McPherron","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6628","key":"2020071616441601300_B9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/387083a0","article-title":"Regulation of skeletal muscle mass in mice by a new TGF-\u03b2 superfamily member","volume":"387","author":"McPherron","year":"1997","journal-title":"Nature"},{"issue":"26","key":"2020071616441601300_B10","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa040933","article-title":"Myostatin mutation associated with gross muscle hypertrophy in a child","volume":"350","author":"Schuelke","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"2020071616441601300_B11","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1083\/jcb.200207056","article-title":"Myostatin negatively regulates satellite cell activation and self-renewal","volume":"162","author":"McCroskery","year":"2003","journal-title":"J Cell Biol"},{"issue":"4","key":"2020071616441601300_B12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/gene.10188","article-title":"Modulating skeletal muscle mass by postnatal, muscle-specific inactivation of the myostatin gene","volume":"35","author":"Grobet","year":"2003","journal-title":"Genesis"},{"issue":"1","key":"2020071616441601300_B13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2005.07.026","article-title":"Prevention and treatment of cancer cachexia: new insights into an old problem","volume":"42","author":"Muscaritoli","year":"2006","journal-title":"Eur J Cancer"},{"issue":"3","key":"2020071616441601300_B14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.critrevonc.2006.06.006","article-title":"Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review","volume":"60","author":"Alibhai","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"2020071616441601300_B15","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/ajcn\/83.4.735","article-title":"Cachexia: pathophysiology and clinical relevance","volume":"83","author":"Morley","year":"2006","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"2020071616441601300_B16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1072-7515(03)00382-X","article-title":"Understanding and managing cancer cachexia","volume":"197","author":"MacDonald","year":"2003","journal-title":"J Am Coll Surg"},{"key":"2020071616441601300_B17","doi-asserted-by":"crossref","first-page":"1014S","DOI":"10.1093\/jn\/127.5.1014S","article-title":"Inflammatory and hormonal mediators of cachexia","volume":"127","author":"Roubenoff","year":"1997","journal-title":"J Nutr"},{"issue":"5","key":"2020071616441601300_B18","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1096\/fj.10-176917","article-title":"Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease","volume":"25","author":"Zhang","year":"2011","journal-title":"FASEB J"},{"issue":"1","key":"2020071616441601300_B19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2020071616441601300_B20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"issue":"21","key":"2020071616441601300_B21","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"issue":"9724","key":"2020071616441601300_B22","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","article-title":"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1\u20132 study","volume":"375","author":"Scher","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"2020071616441601300_B23","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.hoc.2006.03.013","article-title":"Androgen deprivation therapy: monitoring and managing the complications","volume":"20","author":"Higano","year":"2006","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"2020071616441601300_B24","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1210\/jcem.86.9.7851","article-title":"The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer","volume":"86","author":"Smith","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2020071616441601300_B25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2020071616441601300_B26","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.urology.2003.10.063","article-title":"Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer","volume":"63","author":"Smith","year":"2004","journal-title":"Urology"},{"issue":"26","key":"2020071616441601300_B27","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2011.38.8850","article-title":"Sarcopenia during androgen-deprivation therapy for prostate cancer","volume":"30","author":"Smith","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020071616441601300_B28","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2005-2507","article-title":"Insulin sensitivity during combined androgen blockade for prostate cancer","volume":"91","author":"Smith","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"27","key":"2020071616441601300_B29","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"issue":"24","key":"2020071616441601300_B30","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy","volume":"24","author":"Braga-Basaria","year":"2006","journal-title":"J Clin Oncol"},{"key":"2020071616441601300_B31","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.4081\/dts.2012.e11","article-title":"Anti-drug antibodies","volume":"2","author":"Warnke","year":"2012","journal-title":"Drugs Ther Studies"},{"issue":"10","key":"2020071616441601300_B32","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","article-title":"Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP","volume":"113","author":"Bussel","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2020071616441601300_B33","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.21338","article-title":"A phase I\/II trial of MYO-029 in adult subjects with muscular dystrophy","volume":"63","author":"Wagner","year":"2008","journal-title":"Ann Neurol"},{"issue":"S17","key":"2020071616441601300_B34","first-page":"S93","article-title":"Treatment of sporadic inclusion body myositis (sIBM) with an anti-activin receptor II antibody","volume":"74","author":"Amato","year":"2013","journal-title":"Ann Neurol"},{"issue":"3","key":"2020071616441601300_B35","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/mus.23539","article-title":"A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers","volume":"47","author":"Attie","year":"2013","journal-title":"Muscle Nerve"},{"issue":"10","key":"2020071616441601300_B36","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/gerona\/glt030","article-title":"Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents","volume":"68","author":"Chiu","year":"2013","journal-title":"J Gerontol Series A Biol Sci Med Sci"},{"issue":"5","key":"2020071616441601300_B37","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/mus.21944","article-title":"Soluble activin receptor type IIB increases forward pulling tension in the mdx mouse","volume":"43","author":"George Carlson","year":"2011","journal-title":"Muscle Nerve"},{"issue":"2","key":"2020071616441601300_B38","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ajpath.2010.10.035","article-title":"Inhibition of activin receptor type IIB increases strength and lifespan in myotubularin-deficient mice","volume":"178","author":"Lawlor","year":"2011","journal-title":"Am J Pathol"},{"issue":"3","key":"2020071616441601300_B39","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ajpath.2010.11.071","article-title":"Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy","volume":"178","author":"Pistilli","year":"2011","journal-title":"Am J Pathol"},{"issue":"6","key":"2020071616441601300_B40","first-page":"6ra15","article-title":"Follistatin gene delivery enhances muscle growth and strength in nonhuman primates","volume":"1","author":"Kota","year":"2009","journal-title":"Sc Transl Med"},{"issue":"11","key":"2020071616441601300_B41","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/ijo.2009.162","article-title":"The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity","volume":"33","author":"Akpan","year":"2009","journal-title":"Int J Obes"},{"issue":"7","key":"2020071616441601300_B42","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1210\/en.2012-1016","article-title":"A novel therapeutic approach to treating obesity through modulation of TGF\u03b2 signaling","volume":"153","author":"Koncarevic","year":"2012","journal-title":"Endocrinology"},{"issue":"1","key":"2020071616441601300_B43","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00125-011-2304-4","article-title":"Inhibition of myostatin protects against diet-induced obesity by enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice","volume":"55","author":"Zhang","year":"2012","journal-title":"Diabetologia"},{"issue":"3","key":"2020071616441601300_B44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1463-1326.2011.01520.x","article-title":"Soluble activin receptor type IIB treatment does not cause fat loss in mice with diet-induced obesity","volume":"14","author":"McPherron","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2020071616441601300_B45","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.2337\/db09-0349","article-title":"Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in Ldlr null mice","volume":"58","author":"Tu","year":"2009","journal-title":"Diabetes"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/99\/10\/E1967\/9108365\/jcem1967.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/99\/10\/E1967\/9108365\/jcem1967.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T23:23:28Z","timestamp":1594941808000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/99\/10\/E1967\/2836183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,1]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2014-1271","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718470089.793502666","asserted-by":"object"}]},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,1]]}}}